Literature DB >> 25466615

Susceptibility to SLE in South Indian Tamils may be influenced by genetic selection pressure on TLR2 and TLR9 genes.

Panneer Devaraju1, Reena Gulati2, Paul T Antony1, C B Mithun1, Vir S Negi3.   

Abstract

INTRODUCTION: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disorder with complex etiology. Genetics plays an important role in lupus pathogenesis through its influence on clinical and autoantibody phenotype of the disease. Toll like receptors (TLR) recognize molecular patterns of pathogens and activate the innate immune system. Their ability to identify nucleic acids makes them suitable candidates for investigation of their role in lupus pathogenesis. Hence, this study was carried out to analyze the G to A and C to T transitions in TLR2 and TLR9 genes respectively and to test their association with lupus susceptibility, clinical and autoantibody phenotypes in South Indian Tamils.
METHOD: Three hundred SLE patients fulfilling ACR 2012 criteria for SLE and 460 age, sex similar, ethnicity matched controls were recruited as cases and controls. TLR2 (R753Q) and TLR9 (-1237C/T) polymorphisms were analyzed by real time PCR.
RESULTS: The TLR2 gene remained monomorphic in patients and controls, the frequency of the homozygous wild type allele being 100% and 99.6% respectively. Hence, it did not confer susceptibility to SLE. The more frequent T allele of TLR9 gene conferred a significant risk to develop SLE (p=0.011, OR 1.69, 95% CI 1.1-2.6). Both the polymorphisms did not influence clinical or autoantibody phenotype of the disease.
CONCLUSION: Prevailing endemic infections in the Indian subcontinent may have exerted a selection pressure resulting in TLR2 gene remaining monomorphic and the TLR9 adapting to a mutation for its increased expression. These may have an additive effect in the presence of other genetic and environmental risk factors to confer susceptibility to SLE in South Indian Tamils.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Polymorphism; SLE; Selection pressure; TLR

Mesh:

Substances:

Year:  2014        PMID: 25466615     DOI: 10.1016/j.molimm.2014.11.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  6 in total

1.  Association of CD40 polymorphisms and haplotype with risk of systemic lupus erythematosus.

Authors:  Cheng-Jiang Wu; Jing Guo; Hong-Cheng Luo; Chuan-Dong Wei; Chun-Fang Wang; Yan Lan; Ye-Sheng Wei
Journal:  Rheumatol Int       Date:  2015-08-21       Impact factor: 2.631

Review 2.  TLR9 polymorphisms and systemic lupus erythematosus risk: an update meta-analysis study.

Authors:  Duan Wang; Chao Zhang; Zongke Zhou; Fuxing Pei
Journal:  Rheumatol Int       Date:  2015-12-07       Impact factor: 2.631

3.  Clinical significance of the single nucleotide polymorphism TLR2 R753Q in heart transplant recipients at risk for cytomegalovirus disease.

Authors:  Martina Schneider; Teresa Matiqi; Michael Kundi; Franz J J Rieder; Martin Andreas; Robert Strassl; Andreas Zuckermann; Christof Jungbauer; Christoph Steininger
Journal:  J Clin Virol       Date:  2016-10-04       Impact factor: 3.168

Review 4.  Comprehensive Assessment of the Association between FCGRs polymorphisms and the risk of systemic lupus erythematosus: Evidence from a Meta-Analysis.

Authors:  Xiao-Wei Zhu; Yong Wang; Yi-Hua Wei; Pian-Pian Zhao; Xiao-Bo Wang; Jing-Jing Rong; Wen-Ying Zhong; Xing-Wei Zhang; Li Wang; Hou-Feng Zheng
Journal:  Sci Rep       Date:  2016-08-19       Impact factor: 4.379

Review 5.  Toll-like receptors in lupus nephritis.

Authors:  Satish Kumar Devarapu; Hans-Joachim Anders
Journal:  J Biomed Sci       Date:  2018-04-12       Impact factor: 8.410

6.  Polymorphisms within Genes Involved in Regulation of the NF-κB Pathway in Patients with Rheumatoid Arthritis.

Authors:  Katarzyna Gębura; Jerzy Świerkot; Barbara Wysoczańska; Lucyna Korman; Beata Nowak; Piotr Wiland; Katarzyna Bogunia-Kubik
Journal:  Int J Mol Sci       Date:  2017-07-04       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.